Acurable, a London, UK- and Seville, Spain-based medical devices company, raised €11M in Series A funding.
The round was led by Kibo Ventures, with participation from Mundi Ventures, Kindred Capital, and Comprador Holdings.
The company intends to use the funds to build out its distribution network to launch its home sleep testing device AcuPebble SA100 across major European markets and in North America, and invest in its development program for new products based on AcuPebble technology that will help simplify the diagnosis and management of other respiratory and cardiovascular conditions.
Led by CEOs Esther Rodriguez-Villegas and Emilio Sanz, Acurable is a medical devices company that creates wearable medical devices intended to be used by patients themselves at home. Its first product AcuPebble SA100 simplifies obstructive sleep apnoea (OSA) detection and monitoring by enabling fully automated testing of patients at home for the first time. AcuPebble SA100 obtained a CE mark in Europe for the automated diagnosis of obstructive sleep apnoea at home, and received FDA 510(k) clearance in the US.
After launching AcuPebble SA100 in the UK and Spain in 2021, Acurable is now looking to scale up in these two countries and expand into further European markets and North America.
FinSMEs
03/10/2022